Oragenics Inc./$OGEN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Oragenics Inc.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
- Ticker
- $OGEN
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 3
- Headquarters
- Lakewood Ranch, United States
- Website
- www.oragenics.com
Oragenics Inc. Metrics
BasicAdvanced
$1.5M
-
-$2.51
1.24
-
Price and volume
Market cap
$1.5M
Beta
1.24
52-week high
$1.22
52-week low
$0.34
Average daily volume
21K
Financial strength
Current ratio
3.015
Quick ratio
2.121
Interest coverage (TTM)
-561.90%
Profitability
Effective tax rate (TTM)
2.00%
Management effectiveness
Return on assets (TTM)
-171.49%
Return on equity (TTM)
-1,307.06%
Valuation
Price to book
0.42
Price to tangible book (TTM)
0.42
Price to free cash flow (TTM)
-0.134
Free cash flow yield (TTM)
-745.55%
Free cash flow per share (TTM)
-2.543
Growth
Earnings per share change (TTM)
-87.98%
3-year earnings per share growth (CAGR)
-75.72%
Oragenics Inc. Financial Performance
Revenues and expenses
Oragenics Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.